A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi